Suven Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was ₹22,541 Mil.
During the past 12 months, Suven Pharmaceuticals's average Total Assets Growth Rate was -3.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 3.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 12.00% per year.
During the past 6 years, Suven Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 19.40%. The lowest was 3.60%. And the median was 9.40%.
Suven Pharmaceuticals Total Assets Historical Data
The historical data trend for Suven Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Suven Pharmaceuticals's Total Assets for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suven Pharmaceuticals (BOM:543064) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Suven Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Suven Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Suven Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Suven Pharmaceuticals (BOM:543064) Business Description
Suven Pharmaceuticals Ltd is engaged in the development and manufacturing of Intermediates, Active Pharmaceutical Ingredients (API), specialty chemicals and formulated drugs under Contract Research and Manufacturing Services (CRAMS) for global pharmaceutical, biotechnology and chemical companies. The company has single operating segment that is Pharmaceuticals Manufacturing & Services and its geographical segments include India; the USA; Europe and the Rest of the World. The company derives a majority of revenue from the Europe segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BOM:543064 has been successfully added to your 